EE04341B1 - Torasemiidi kristallmodifikatsioon N, selle valmistamismeetod, kasutamine ja ravimvorm - Google Patents
Torasemiidi kristallmodifikatsioon N, selle valmistamismeetod, kasutamine ja ravimvormInfo
- Publication number
- EE04341B1 EE04341B1 EEP200100194A EEP200100194A EE04341B1 EE 04341 B1 EE04341 B1 EE 04341B1 EE P200100194 A EEP200100194 A EE P200100194A EE P200100194 A EEP200100194 A EE P200100194A EE 04341 B1 EE04341 B1 EE 04341B1
- Authority
- EE
- Estonia
- Prior art keywords
- torasemide
- preparation
- new
- form iii
- dosage form
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title abstract 5
- 229960005461 torasemide Drugs 0.000 title abstract 5
- 230000004048 modification Effects 0.000 title abstract 3
- 238000012986 modification Methods 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 2
- 230000020477 pH reduction Effects 0.000 abstract 2
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Liquid Crystal Substances (AREA)
- Liquid Crystal (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR980532A HRP980532B1 (en) | 1998-10-02 | 1998-10-02 | Novel crystalline torasemide modification |
PCT/HR1999/000023 WO2000020395A1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200100194A EE200100194A (et) | 2002-06-17 |
EE04341B1 true EE04341B1 (et) | 2004-08-16 |
Family
ID=10946825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200100194A EE04341B1 (et) | 1998-10-02 | 1999-10-01 | Torasemiidi kristallmodifikatsioon N, selle valmistamismeetod, kasutamine ja ravimvorm |
Country Status (32)
Country | Link |
---|---|
US (5) | US6399637B1 (de) |
EP (1) | EP1117643B1 (de) |
JP (1) | JP2002526532A (de) |
KR (1) | KR100437307B1 (de) |
CN (1) | CN1125049C (de) |
AT (1) | ATE286024T1 (de) |
AU (1) | AU759291B2 (de) |
BG (1) | BG105485A (de) |
BR (1) | BR9915018A (de) |
CA (1) | CA2345789A1 (de) |
CZ (1) | CZ20011031A3 (de) |
DE (2) | DE29924789U1 (de) |
DK (1) | DK1117643T3 (de) |
EE (1) | EE04341B1 (de) |
ES (1) | ES2237158T3 (de) |
HK (1) | HK1040250B (de) |
HR (1) | HRP980532B1 (de) |
HU (1) | HUP0104009A3 (de) |
ID (1) | ID29931A (de) |
IL (1) | IL142150A0 (de) |
NO (1) | NO317107B1 (de) |
NZ (1) | NZ510898A (de) |
PL (1) | PL346975A1 (de) |
PT (1) | PT1117643E (de) |
RU (1) | RU2210569C2 (de) |
SI (1) | SI1117643T1 (de) |
SK (1) | SK4232001A3 (de) |
TR (1) | TR200100909T2 (de) |
UA (1) | UA72895C2 (de) |
WO (1) | WO2000020395A1 (de) |
YU (1) | YU24001A (de) |
ZA (1) | ZA200102451B (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6394707B1 (en) | 1997-05-08 | 2002-05-28 | Jack Kennedy Metal Products & Buildings, Inc. | Yieldable mine roof support |
HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
CZ2002404A3 (cs) * | 1999-08-11 | 2002-06-12 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy torsemidu |
DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
HRP20000162B1 (en) | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
HRP20000328A2 (en) * | 2000-05-19 | 2002-02-28 | Pliva Farmaceutska Ind Dionik | Novel polymorph v of torasemide |
IN192178B (de) * | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
HRP20020603B1 (en) * | 2002-07-19 | 2008-11-30 | Pliva D.D. | New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide |
CA2424644A1 (en) * | 2003-04-07 | 2004-10-07 | David John Mckenzie | Preparation of torasemide |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
JP4406845B2 (ja) * | 2007-02-20 | 2010-02-03 | トヨタ自動車株式会社 | 二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法 |
EP2705843A1 (de) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutische Ansätze zur Behandlung von Epilepsie und zugehöriger Erkrankungen durch Reduzierung der Epileptogenese |
CN104370805B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
CN106038500A (zh) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | 一种托拉塞米片 |
CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
CN117486789A (zh) * | 2023-12-29 | 2024-02-02 | 江西中医药大学 | 一种托拉塞米共晶盐及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
US4055650A (en) * | 1974-04-17 | 1977-10-25 | A. Christiaens Societe Anonyme | Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines |
US4473693A (en) | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
-
1998
- 1998-10-02 HR HR980532A patent/HRP980532B1/xx not_active IP Right Cessation
-
1999
- 1999-10-01 CN CN99811710A patent/CN1125049C/zh not_active Expired - Fee Related
- 1999-10-01 TR TR2001/00909T patent/TR200100909T2/xx unknown
- 1999-10-01 DK DK99949272T patent/DK1117643T3/da active
- 1999-10-01 WO PCT/HR1999/000023 patent/WO2000020395A1/en active IP Right Grant
- 1999-10-01 ES ES99949272T patent/ES2237158T3/es not_active Expired - Lifetime
- 1999-10-01 ZA ZA200102451A patent/ZA200102451B/en unknown
- 1999-10-01 UA UA2001031966A patent/UA72895C2/uk unknown
- 1999-10-01 DE DE29924789U patent/DE29924789U1/de not_active Expired - Lifetime
- 1999-10-01 EE EEP200100194A patent/EE04341B1/xx not_active IP Right Cessation
- 1999-10-01 CZ CZ20011031A patent/CZ20011031A3/cs unknown
- 1999-10-01 YU YU24001A patent/YU24001A/sh unknown
- 1999-10-01 IL IL14215099A patent/IL142150A0/xx unknown
- 1999-10-01 HU HU0104009A patent/HUP0104009A3/hu unknown
- 1999-10-01 NZ NZ510898A patent/NZ510898A/xx unknown
- 1999-10-01 RU RU2001111831/04A patent/RU2210569C2/ru not_active IP Right Cessation
- 1999-10-01 PL PL99346975A patent/PL346975A1/xx not_active Application Discontinuation
- 1999-10-01 JP JP2000574512A patent/JP2002526532A/ja active Pending
- 1999-10-01 DE DE69922977T patent/DE69922977C5/de not_active Revoked
- 1999-10-01 SK SK423-2001A patent/SK4232001A3/sk not_active Application Discontinuation
- 1999-10-01 EP EP99949272A patent/EP1117643B1/de not_active Revoked
- 1999-10-01 CA CA002345789A patent/CA2345789A1/en not_active Abandoned
- 1999-10-01 BR BR9915018-2A patent/BR9915018A/pt not_active IP Right Cessation
- 1999-10-01 AU AU62240/99A patent/AU759291B2/en not_active Ceased
- 1999-10-01 AT AT99949272T patent/ATE286024T1/de not_active IP Right Cessation
- 1999-10-01 SI SI9930744T patent/SI1117643T1/xx unknown
- 1999-10-01 ID IDW20010958A patent/ID29931A/id unknown
- 1999-10-01 KR KR10-2001-7004079A patent/KR100437307B1/ko not_active IP Right Cessation
- 1999-10-01 PT PT99949272T patent/PT1117643E/pt unknown
- 1999-11-05 US US09/434,439 patent/US6399637B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 NO NO20011633A patent/NO317107B1/no unknown
- 2001-05-02 BG BG105485A patent/BG105485A/xx unknown
-
2002
- 2002-03-13 US US10/096,277 patent/US6833379B2/en not_active Expired - Fee Related
- 2002-03-15 HK HK02102011.9A patent/HK1040250B/zh not_active IP Right Cessation
-
2004
- 2004-06-21 US US10/871,667 patent/US20040229919A1/en not_active Abandoned
-
2006
- 2006-02-21 US US11/357,109 patent/US20060205951A1/en not_active Abandoned
-
2007
- 2007-07-03 US US11/822,274 patent/US20070276015A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE04341B1 (et) | Torasemiidi kristallmodifikatsioon N, selle valmistamismeetod, kasutamine ja ravimvorm | |
HRP20000092C1 (en) | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof | |
WO2001053237A3 (en) | Production of monocycloalkyl aromatic compounds | |
DK0763263T3 (da) | Katodemateriale til lithiumsekundærbatterier og en fremgangsmåde og et precursormateriale til fremstilling deraf | |
BR9909567B1 (pt) | composição agricolamente ativa, processo para a preparação de um composto, processos eletroquìmicos para a preparação de um composto e de hidróxido de n,n-dimetilpiperidìnio, composto, concentrado de suspensão, e, processo para regular o crescimento de planta. | |
NO166528C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive naftalen- og indanderivater. | |
IE800208L (en) | Production of isosorbide-5-nitrate | |
ES8605147A1 (es) | Procedimiento de preparar compuestos para estimular el cre- cimiento y-o la produccion de leche de animales domesticos | |
EP1069122A4 (de) | Verfahren zur herstellung von 5-hydroxybenzo(b)thiophen-3-carbonsäure | |
EP1195356A4 (de) | Plattenförmiges metalltitanat-komposit und verfahren zu dessen herstellung | |
IE780504L (en) | Preparing 5-(4-hydroxyphenyl) hydantoin | |
CA2089193A1 (en) | Diacetyl production | |
ES2033703T3 (es) | Procedimiento para preparar acido nicotinico en cristales gruesos de alta pureza. | |
EP0922704A4 (de) | Verfahren zur herstellung und zwischenprodukt der 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)-propionsäure | |
AU2115488A (en) | Substituted phenylthioureseas, phenylisothioureas and phenylcabordiimides, their salts with organic and inorganic acids, processes and intermediates for their preparation, pesticidal compostions containing them, and their use in the control of pests. | |
ES2007346A6 (es) | Un metodo de preparar derivados de oligoglucosilmoranolina | |
JPS6470479A (en) | Heterocylic carboxylic acid derivative, production thereof and agricultural and horticultural germicide containing said derivative as active ingredient | |
NO20004313L (no) | Fremgangsmåte for fremstilling av 5-lipoksygenase-inhibitorer med varierte heterocycliske ringsystemer | |
Podder et al. | Crystal structure of phenylpropanolamine hydrochloride | |
Hamou et al. | Study of the Kinetics of Crystallization of Amorphous Selenium. Influence of Substrate Treatments | |
SATTER | ARTHUR W. GALSTON | |
Zhang et al. | On low cost BAS(barium aluminosilicate) glass-ceramics and their crystallization behavior | |
AU610015C (en) | 3-(substituted phenyl) pyrazole derivatives, salts thereof, herbicides therefrom, and process for producing said derivatives or salts | |
AU4086589A (en) | 3-(substituted phenyl) pyrazole derivatives, salts thereof, herbicides therefrom, and process for producing said derivatives or salts | |
JPS6456316A (en) | Production of sodium carbonate heptahydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB1A | Change in the ownership or in the address of the owner | ||
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
GB1A | Change in the ownership or in the address of the owner | ||
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20061001 |